The text starts here.

News Release

November 21, 2003

Eisai Commences US Legal Action Over Aciphex(R) ANDA Filings

Eisai Co., Ltd.
Eisai Inc.
Eisai Commences US Legal Action Over Aciphex(R) ANDA Filings

Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito) and Eisai Inc. (Headquarters: New Jersey, Chairman and CEO: Soichi Matsuno) announce that they filed lawsuits against Dr. Reddy's Laboratories1) and Teva Pharmaceuticals2) regarding their submissions of abbreviated new drug applications (ANDA) to the FDA for Aciphex(R) (Active Ingredient Name: rabeprazole sodium, Product Name in Japan: Pariet(R)). The patent infringement actions were filed in the U.S. District Court for the Southern District of New York in New York City.

Eisai believes that its rabeprazole composition of matter patent is valid until its expiration date of May 8, 2013. Eisai intends to vigorously enforce and defend that patent.

Aciphex(R) is classified as a proton pump inhibitor that effectively suppresses gastric acid secretion while inhibiting enzyme activity during the last phase of stomach acid secretion. Aciphex(R) was launched in the U.S. in 1999 and is currently marketed in 70 countries worldwide, including Japan, the U.K. and Germany.

Eisai is a research-based pharmaceutical company that discovers, develops and markets new chemical compounds to satisfy global unmet medical needs.

  1): Dr. Reddy's Laboratories, Inc. (Headquarters: New Jersey) and its parent company Dr. Reddy's Laboratories, Ltd. (Headquarters: India)
2): Teva Pharmaceuticals USA (Headquarters: Pennsylvania) and its parent company Teva Pharmaceutical Industries, Ltd. (Headquarters: Israel)

Public Relations Department
Eisai Co., Ltd.
Cathy Pollini
Corporate Public Relations
Eisai Inc.